Pancreatic Cancer Research

ResearcherChampalimaud FoundationActive in the last 2 years

Peter J. Bailey

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0857-2041; OpenAlex author ID A5102937267. Sources: OpenAlex.

Their work

Papers
42 (first author 7, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
191
Papers, trials and grants by year

2014: 1 paper · 2015: 2 papers · 2016: 4 papers · 2017: 5 papers · 2018: 1 paper · 2019: 4 papers · 2020: 3 papers · 2021: 6 papers · 2022: 4 papers · 2023: 3 papers · 2024: 5 papers · 2025: 2 papers · 2026: 2 papers

Papers 42

  1. Pancreatic Cancer Frequently Infiltrates the TRIANGLE Compartment: A Surgical Option to Prevent Local Recurrence. Co-author DOI 10.1097/as9.0000000000000672↗
  2. The Role of Circulating Tumor DNA in Surgical Management of Pancreatic Cancer: Systematic Review and Meta-analysis. Co-author DOI 10.1097/sla.0000000000007036↗
  3. MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. Co-author DOI 10.1038/s41586-025-08721-9↗
  4. Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. Co-author DOI 10.1200/jco.24.01118↗
  5. Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer. Co-author DOI 10.1016/j.immuni.2024.04.021↗
  6. Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response. Co-author DOI 10.1016/j.tranon.2024.102109↗
  7. Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. Co-author DOI 10.1136/gutjnl-2023-329807↗
  8. Tumour plasticity and tumour microenvironment interactions as potential immunologic targets for pancreatic cancer treatment. Co-author DOI 10.21037/cco-24-72↗
  9. ESMO 2023 pancreatic cancer guidelines signal stepwise progress. First author DOI 10.21037/hbsn-24-37↗
  10. Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. Last author DOI 10.1038/s43018-023-00628-6↗
  11. Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival. Co-author DOI 10.1093/function/zqad011↗
  12. Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer. Co-author DOI 10.3389/fcell.2023.1179559↗
  13. Loss of FGFR4 promotes the malignant phenotype of PDAC. Co-author DOI 10.1038/s41388-022-02432-5↗
  14. CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. Co-author DOI 10.1186/s13046-022-02443-w↗
  15. Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC. First author DOI 10.3389/fcell.2022.816517↗
  16. Editorial: Translational Insights Into Pancreatic Ductal Adenocarcinoma. First author DOI 10.3389/fcell.2022.875836↗
  17. Poly(ADP-ribose) polymerase inhibition in pancreatic cancer. First author DOI 10.1002/gcc.22932↗
  18. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.09.043↗
  19. Perioperative immunotherapy for pancreatic cancer is on its way. First author DOI 10.21037/hbsn-21-238↗
  20. Clinical Impact of Molecular Subtyping of Pancreatic Cancer. Co-author DOI 10.3389/fcell.2021.743908↗
  21. Deconstructing Pancreatic Cancer Using Next Generation-Omic Technologies-From Discovery to Knowledge-Guided Platforms for Better Patient Management. Last author DOI 10.3389/fcell.2021.795735↗
  22. Deep Learning Improves Pancreatic Cancer Diagnosis Using RNA-Based Variants. Co-author DOI 10.3390/cancers13112654↗
  23. Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2020.05.010↗
  24. Using Chromatin Accessibility to Delineate Therapeutic Subtypes in Pancreatic Cancer Patient-Derived Cell Lines. Last author DOI 10.1016/j.xpro.2020.100079↗
  25. Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003143↗
  26. The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Co-author DOI 10.1002/path.5320↗
  27. Molecular subtypes of pancreatic cancer. First author DOI 10.1038/s41575-019-0109-y↗
  28. Prolactin Promotes Fibrosis and Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-18-3064↗
  29. CRISPR Cas9 in Pancreatic Cancer Research. First author DOI 10.3389/fcell.2019.00239↗
  30. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Co-author DOI 10.1038/s41389-018-0096-9↗
  31. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. Co-author DOI 10.1038/bjc.2017.40↗
  32. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Co-author DOI 10.1038/ncomms14294↗
  33. Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ng.3861↗
  34. Hypermutation In Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.09.060↗
  35. Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development. Co-author DOI 10.1158/1078-0432.ccr-16-2411↗
  36. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2016.04.014↗
  37. Genomic analyses identify molecular subtypes of pancreatic cancer. Co-author DOI 10.1038/nature16965↗
  38. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/srep35848↗
  39. PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance. Co-author DOI 10.1101/gad.291021.116↗
  40. Whole genomes redefine the mutational landscape of pancreatic cancer. Co-author DOI 10.1038/nature14169↗
  41. Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug effic… Co-author DOI 10.15252/emmm.201404827↗
  42. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Co-author DOI 10.1002/ijc.28765↗

Closest collaborators

The 25 strongest of 191 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. John P. Neoptolemos · 11 shared papers, 2021–2025 · strength 1.97
  2. Christoph Springfeld · 10 shared papers, 2021–2025 · strength 1.78
  3. Andrew Victor Biankin · 16 shared papers, 2014–2022 · strength 1.10
  4. Markus Wolfgang Büchler · 6 shared papers, 2021–2026 · strength 1.08
  5. David Kuang-Fu Chang · 15 shared papers, 2014–2022 · strength 1.02
  6. Thilo Hackert · 6 shared papers, 2021–2025 · strength 0.90
  7. Xu Zhou · 5 shared papers, 2021–2024 · strength 0.73
  8. Simon T. Barry · 5 shared papers, 2016–2023 · strength 0.69
  9. Rita Teresa Lawlor · 6 shared papers, 2014–2025 · strength 0.68
  10. Aldo Scarpa · 6 shared papers, 2014–2025 · strength 0.68
  11. Susanne Roth · 4 shared papers, 2021–2024 · strength 0.65
  12. Christian P. Pilarsky · 5 shared papers, 2019–2025 · strength 0.64
  13. Vincenzo Corbo · 5 shared papers, 2014–2025 · strength 0.61
  14. Jingyu An · 4 shared papers, 2021–2024 · strength 0.54
  15. Vera Oliveira · 2 shared papers, 2026 · strength 0.49
  16. Gil Gonçalves · 2 shared papers, 2026 · strength 0.49
  17. Filipe C. Borges · 2 shared papers, 2026 · strength 0.49
  18. Daniel Schreyer · 3 shared papers, 2021–2025 · strength 0.48
  19. Francesca Lupo · 3 shared papers, 2022–2025 · strength 0.43
  20. Antonia Malinova · 3 shared papers, 2022–2025 · strength 0.43
  21. Sabrina L. D’Agosto · 3 shared papers, 2022–2025 · strength 0.43
  22. Lisa Veghini · 3 shared papers, 2022–2025 · strength 0.43
  23. Elena Fiorini · 3 shared papers, 2022–2025 · strength 0.43
  24. David Arthur Tuveson · 3 shared papers, 2017–2025 · strength 0.38
  25. Maarten F. Bijlsma · 2 shared papers, 2018–2022 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.